PCRX Pacira BioSciences, Inc.
$24.76 -1.16%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.16%
YTD
+4.80%
P/E
68.35
P/B
1.61
ROE
2.1%
Div yield
—
Beta
0.29
Market cap
$1.0B
RSI (14)
46
Next earnings
Nov 4, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$25.13
Close
$24.76
VWAP (n/a)
—
Day high
$25.25
Day low
$24.56
Volume
493K
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Pacira BioSciences (PCRX) On Its Molteni Deal And The Undervalued Narrative
Yahoo Finance · Oct 6
Pacira partners with Molteni for Exparel commercialisation
Yahoo Finance · Oct 6
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
Yahoo Finance · Oct 5
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance · Sep 9
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Yahoo Finance · Sep 3
Pacira (PCRX) Q2 2026 Earnings Call Transcript
Yahoo Finance · Aug 12
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
10-Q Aug 4, 2026 View → 8-K Aug 4, 2026 View → 8-K Jun 30, 2026 View → 8-K Jun 11, 2026 View → 10-Q Apr 30, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell PCRX. Try it in the Lab to size a position and see the risk.